Search

Your search keyword '"Chan You, Seng"' showing total 11 results
Start Over Author "Chan You, Seng"
11 results on '"Chan You, Seng"'

6. Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe

Author

Moreno-Martos, David, primary, Verhamme, Katia, additional, Ostropolets, Anna, additional, Kostka, Kristin, additional, Duarte-Sales, Talita, additional, Prieto-Alhambra, Daniel, additional, Alshammari, Thamir M, additional, Alghoul, Heba, additional, Ahmed, Waheed-Ul-Rahman, additional, Blacketer, Clair, additional, DuVall, Scott, additional, Lai, Lana, additional, Matheny, Michael, additional, Nyberg, Fredrik, additional, Posada, Jose, additional, Rijnbeek, Peter, additional, Spotnitz, Matthew, additional, Sena, Anthony, additional, Shah, Nigam, additional, Suchard, Marc, additional, Chan You, Seng, additional, Hripcsak, George, additional, Ryan, Patrick, additional, and Morales, Daniel, additional

Published
2023
Full Text
View/download PDF

7. International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients

Author

Nishimura, Akihiko, primary, Xie, Junqing, additional, Kostka, Kristin, additional, Duarte-Salles, Talita, additional, Fernández Bertolín, Sergio, additional, Aragón, María, additional, Blacketer, Clair, additional, Shoaibi, Azza, additional, DuVall, Scott L., additional, Lynch, Kristine, additional, Matheny, Michael E., additional, Falconer, Thomas, additional, Morales, Daniel R., additional, Conover, Mitchell M., additional, Chan You, Seng, additional, Pratt, Nicole, additional, Weaver, James, additional, Sena, Anthony G., additional, Schuemie, Martijn J., additional, Reps, Jenna, additional, Reich, Christian, additional, Rijnbeek, Peter R., additional, Ryan, Patrick B., additional, Hripcsak, George, additional, Prieto-Alhambra, Daniel, additional, and Suchard, Marc A., additional

Published
2022
Full Text
View/download PDF

9. Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe

Author

Moreno-Martos, David, primary, Verhamme, Katia, additional, Ostropolets, Anna, additional, Kostka, Kristin, additional, Duarte-Sales, Talita, additional, Prieto-Alhambra, Daniel, additional, Alshammari, Thamir M, additional, Alghoul, Heba, additional, Ahmed, Waheed-Ul-Rahman, additional, Blacketer, Clair, additional, DuVall, Scott, additional, Lai, Lana, additional, Matheny, Michael, additional, Nyberg, Fredrik, additional, Posada, Jose, additional, Rijnbeek, Peter, additional, Spotnitz, Matthew, additional, Sena, Anthony, additional, Shah, Nigam, additional, Suchard, Marc, additional, Chan You, Seng, additional, Hripcsak, George, additional, Ryan, Patrick, additional, and Morales, Daniel, additional

Published
2022
Full Text
View/download PDF

11. Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients

Author

Martijn J. Schuemie, Christian G. Reich, Rae Woong Park, Ruijun Chen, David Madigan, Nicole L. Pratt, George Hripcsak, Jon Duke, Sungha Park, Seng Chan You, Marc A. Suchard, Steven Shea, Patrick B. Ryan, Harlan M. Krumholz, Chan You, Seng, Krumholz, Harlan M, Suchard, Marc A, Schuemie, Martijn J, Hripcsak, George, Chen, Ruijun, Shea, Steven, Duke, Jon, Pratt, Nicole, Reich, Christian G, Madigan, David, Ryan, Patrick B, Woong Park, Rae, and Park, Sungha

Subjects
Adult, Male, medicine.medical_specialty, hypertension, Databases, Factual, Scale (ratio), First line, Adrenergic beta-Antagonists, Blood Pressure, 030204 cardiovascular system & hematology, Article, Nebivolol, 03 medical and health sciences, 0302 clinical medicine, β-blocker, Internal Medicine, Humans, Medicine, 030212 general & internal medicine, Stroke, Antihypertensive Agents, business.industry, blood pressure, Middle Aged, antihypertensive agents, Atenolol, medicine.disease, stroke, atenolol, Treatment Outcome, Blood pressure, monotherapy, Hypertension, Emergency medicine, Carvedilol, Female, Observational study, business, medicine.drug
Abstract

Evidence for the effectiveness and safety of the third-generation beta-blockers other than atenolol in hypertension remains scarce. We assessed the effectiveness and safety of beta-blockers as first-line treatment for hypertension using three databases in the United States: two administrative claim databases and one electronic health record-based database from 2001 to 2018. In each database, comparative effectiveness of beta-blockers for the risks of acute myocardial infarction, stroke, and hospitalization for heart failure was assessed, using large-scale propensity adjustment and empirical calibration. Estimates were combined across databases using random-effects meta-analyses. Overall, 118,133 and 267,891 patients initiated third-generation beta-blockers (carvedilol and nebivolol) or atenolol, respectively. The pooled hazard ratios of acute myocardial infarction, stroke, hospitalization for heart failure, and most metabolic complications were not different between the third-generation beta-blockers versus atenolol after propensity score matching and empirical calibration (hazard ratio 1.07, 95% CI 0.74 to 1.55 for acute myocardial infarction; hazard ratio 1.06, 95% CI 0.87 to 1.31 for stroke; hazard ratio 1.46, 95% CI 0.99 to 2.24 for hospitalized heart failure). Third-generation beta-blockers were associated with significantly higher risk of stroke than angiotensin-converting enzyme inhibitors (hazard ratio 1.29, 95% CI 1.03 to 1.72), and thiazide diuretics (hazard ratio 1.56, 95% CI 1.17 to 2.20). In conclusion, this study found many patients with first-line beta-blocker monotherapy for hypertension and no statistically significant differences in the effectiveness and safety comparing atenolol with third-generation beta-blockers. Patients on third-generation beta-blockers had a higher risk of stroke than those on angiotensin-converting enzyme inhibitors and thiazide diuretics.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results